This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CHEK Check-Cap (CHEK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Check-Cap Stock (NASDAQ:CHEK) Get Check-Cap alerts:Sign Up Key Stats Today's Range$1.50▼$1.6750-Day Range$1.21▼$1.9852-Week Range$0.59▼$3.13Volume58,962 shsAverage Volume1.29 million shsMarket Capitalization$9.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Check-Cap Ltd. (NASDAQ: CHEK) is a clinical-stage medical device company focused on the development of non-invasive screening technologies for colorectal cancer. The company’s lead product, the C-Scan® system, is designed to provide a full-colonic 360° visualization by combining an ingestible X-ray emitting capsule with an external detector array and proprietary image reconstruction algorithms. Intended as a minimally invasive alternative to traditional colonoscopy, the C-Scan system aims to improve patient comfort and compliance while maintaining high sensitivity for detecting polyps and early-stage lesions. The C-Scan procedure involves the patient ingesting the capsule, which passes naturally through the gastrointestinal tract. During its transit, the capsule emits low-dose X-rays that are captured by detectors worn externally around the abdomen. Data collected by the system are then processed by software to generate high-resolution, panoramic images of the colon lining. This approach seeks to address limitations of stool-based tests and virtual colonoscopy, offering clinicians detailed anatomical views without sedation or insufflation. Founded in Israel, Check-Cap maintains its headquarters in Caesarea along with operations in the United States, where it conducts clinical trials and regulatory activities. The company has completed multiple early-stage studies and has been advancing toward pivotal trials required for regulatory clearances in both European and U.S. markets. Check-Cap’s development strategy includes collaborations with leading gastroenterology centers to validate clinical efficacy and support future commercial rollout. Check-Cap is led by a management team with extensive experience in medical imaging, device development and gastroenterology. The company continues to advance its C-Scan platform through ongoing research, regulatory engagement and strategic partnerships, aiming to transform colorectal cancer screening by offering a patient-friendly solution with broad applicability in routine preventive care.AI Generated. May Contain Errors. Read More Receive CHEK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Check-Cap and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CHEK Stock News HeadlinesMBody AI Ltd. Completes Transformational Merger and Rebrand from Check-CapSeptember 22, 2026 | tipranks.comCheck-Cap Raises $10 Million in Public Share Offering, Adds Lock-Up to Support AI Robotics ExpansionAugust 28, 2026 | tipranks.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 24 at 1:00 AM | Weiss Ratings (Ad)Check-Cap Highlights MBody AI’s North American Robotics Expansion as Merger AdvancesJune 29, 2026 | tipranks.com3 Penny Stocks to Watch Now, 1/27/26January 27, 2026 | tipranks.comCheck-Cap Swings to Profit and Positive Equity on Debt Conversion in First Half 2025December 30, 2025 | tipranks.comCheck-Cap Transitions to MBody AI with New Nasdaq Ticker ‘MBAI’December 1, 2025 | tipranks.comCheck-Cap Shareholders Approve Transformational Merger with MBody AINovember 17, 2025 | tipranks.comSee More Headlines CHEK Stock Analysis - Frequently Asked Questions How were Check-Cap's earnings last quarter? Check-Cap Ltd. (NASDAQ:CHEK) released its earnings results on Monday, November, 27th. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.39. When did Check-Cap's stock split? Shares of Check-Cap reverse split on the morning of Friday, November 25th 2022.The 1-20 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Check-Cap IPO? Check-Cap (CHEK) raised $13 million in an initial public offering on Thursday, February 19th 2015. The company issued 1,200,000 shares at a price of $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group acted as the underwriters for the IPO and Feltl and Company was co-manager. What other stocks do shareholders of Check-Cap own? Based on aggregate information from My MarketBeat watchlists, some other companies that Check-Cap investors own include Bionano Genomics (BNGO), NIO (NIO), Palantir Technologies (PLTR), Plug Power (PLUG), SNDL (SNDL), NVIDIA (NVDA) and Ocugen (OCGN). Company Calendar Last Earnings11/27/2023Today10/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:CHEK CIK1610590 Webwww.check-cap.com Phone972546706451Fax972-4821-1267Employees80Year Founded2005Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-6.46Miscellaneous Outstanding Shares5,851,000Free Float5,823,000Market Cap$9.45 million OptionableNot Optionable Beta0.41 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CHEK) was last updated on 11/26/2025 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Check-Cap Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Check-Cap With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.